Prospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
Phase of Trial: Phase IV
Latest Information Update: 03 Dec 2018
At a glance
- Drugs Susoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Baxalta
- 26 Nov 2018 Planned End Date changed from 30 Sep 2021 to 31 May 2021.
- 26 Nov 2018 Planned primary completion date changed from 30 Sep 2021 to 31 May 2021.
- 29 Jun 2017 New trial record